Lexicon Pharmaceuticals is a biopharmaceutical company engaged in the discovery of breakthrough treatments for human disease. Currently, the company has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis. The company has identified more than 100 promising drug targets using its proprietary gene knockout technology, focusing drug discovery efforts on these targets to create an extensive pipeline of clinical and preclinical programs. For more information, visit the company’s Web site at www.lexpharma.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: